Startseite>>Signaling Pathways>> GPCR/G protein>> Adrenergic Receptor>>(±)-Penbutolol-d9 hydrochloride

(±)-Penbutolol-d9 hydrochloride

Katalog-Nr.GC62727

(±)-Penbutolol-d9 ((Rac)-Penbutolol-d9)-Hydrochlorid ist ein mit Deuterium markiertes (±)-Penbutolol-Hydrochlorid.

Products are for research use only. Not for human use. We do not sell to patients.

(±)-Penbutolol-d9 hydrochloride Chemische Struktur

Cas No.: 1346605-01-3

Größe Preis Lagerbestand Menge
1 mg
405,00 $
Auf Lager
5 mg
1.125,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

(±)-Penbutolol-d9 ((Rac)-Penbutolol-d9) hydrochloride is a deuterium labeled (±)-Penbutolol hydrochloride. (+)-Penbutolol hydrochloride is a β-adrenoceptor antagonist, with an IC50 of 0.74 μM[1].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[2].

[1]. Chen M, et al. Effects of beta-adrenoceptor antagonists on Ca(2+)-overload induced by lysophosphatidylcholine in rat isolated cardiomyocytes. Br J Pharmacol. 1996 Jun;118(4):865-70.
[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

Bewertungen

Review for (±)-Penbutolol-d9 hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (±)-Penbutolol-d9 hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.